Answers are grounded in this paper and cite their sources.
Objective Triple-negative breast cancer (TNBC) is a biologically heterogeneous breast cancer subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (HER2), limiting targeted treatment options and contributing to poor clinical outcomes. This review summarizes the pathological features of TNBC and highlights the theranostic potential of circulating tumour DNA (ctDNA) and programmed death-ligand 1 (PD-L1) as biomarkers for precision oncology. Data Sources Relevant literature on TNBC, ctDNA, and PD-L1 was reviewed, focusing on their molecular characteristics, detection technologies, clinical applications, pivotal clinical trials, and challenges associated with clinical translation. Data Summary ctDNA enables minimally invasive, real-time molecular profiling for detecting tumor-specific genetic alterations, monitoring treatment response, assessing minimal residual disease, and identifying disease recurrence. PD-L1 is a key immune biomarker that predicts responsiveness to immune checkpoint inhibitors. Landmark clinical trials, including KEYNOTE-355, KEYNOTE-522, IMpassion130, IMpassion131, c-TRAK-TN, and BRE12-158, demonstrate that PD-L1-guided immunotherapy improves patient selection and clinical outcomes, whereas ctDNA-guided surveillance facilitates early detection of molecular relapse and risk-adapted therapeutic intervention. Emerging biomarker-driven combination strategies integrating immunotherapy with targeted therapies further support personalized treatment approaches. Despite these advances, challenges related to assay sensitivity, tumor heterogeneity, and biomarker standardization remain. Conclusions ctDNA and PD-L1 have evolved into clinically meaningful theranostic biomarkers that support patient stratification, treatment selection, and disease monitoring in TNBC. Continued validation through prospective clinical trials and standardized biomarker assessment is essential for their routine implementation in precision oncology and for improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
SB et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: